{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:17:18Z","timestamp":1790086638320,"version":"4.0.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>This phase 1b study evaluated safety and efficacy of acalabrutinib, venetoclax, and rituximab (AVR) in treatment-naive mantle cell lymphoma (TN MCL). Patients received acalabrutinib from cycle 1 until progressive disease (PD) or undue toxicity, rituximab for 6 cycles with maintenance every other cycle through cycle 24 or until PD, and venetoclax, beginning at cycle 2, for 24 cycles. Twenty-one patients were enrolled; 95.2% completed induction (6 AVR cycles) and 47.6% continued acalabrutinib maintenance. Thirteen (61.9%) patients had grade 3-4 adverse events (AEs), most commonly neutropenia (33.3%). Seven (33.3%) patients had COVID-19 infection (6 [28.6%] serious AEs and 5 [23.8%] deaths, all among unvaccinated patients). There was no grade \u22653 atrial fibrillation, ventricular tachyarrhythmias, major hemorrhages, or tumor lysis syndrome. Overall response rate (ORR) was 100% (95% CI, 83.9-100.0) with 71.4% complete response. With median follow-up of 27.8\u00a0months, median progression-free survival (PFS) and overall survival (OS) were not reached. PFS rates at 1 and 2 years were 90.5% (95%\u00a0CI, 67.0-97.5) and 63.2% (95%\u00a0CI, 34.7-82.0), respectively; both were 95% after censoring COVID-19 deaths. OS rates at 1 and 2 years were 95.2% (95%\u00a0CI, 70.7-99.3) and 75.2% (95%\u00a0CI, 50.3-88.9), respectively; both were 100% after censoring COVID-19 deaths. Overall, 87.5% of patients with available minimal residual disease (MRD) data achieved MRD negativity (10\u20136; next-generation sequencing) during treatment. AVR represents a chemotherapy-free regimen for TN MCL and resulted in high ORR and high rates of MRD negativity. The trial was registered at www.ClinicalTrials.gov as #NCT02717624.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012424","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T13:59:16Z","timestamp":1716472756000},"page":"4539-4548","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"first","affiliation":[{"name":"1Department of Lymphoma\/Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, The University of Texas, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami J.","family":"Maddocks","sequence":"additional","affiliation":[{"name":"3Division of Hematology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-9672","authenticated-orcid":false,"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[{"name":"4University of Michigan Comprehensive Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"5University of Washington\/Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gallinson","sequence":"additional","affiliation":[{"name":"6Summit Medical Group, Florham Park, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Calvo","sequence":"additional","affiliation":[{"name":"7AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Chuan","family":"Wun","sequence":"additional","affiliation":[{"name":"8AstraZeneca, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerendra","family":"Munugalavadla","sequence":"additional","affiliation":[{"name":"8AstraZeneca, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"9Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"issue":"14","key":"2024091012503875500_bib1","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1182\/bloodadvances.2022007247","article-title":"Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma","volume":"6","author":"Narkhede","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2024091012503875500_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"2024091012503875500_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"9873","key":"2024091012503875500_bib4","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"2024091012503875500_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17474086.2022.2042246","article-title":"Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-na\u00efve patients with CLL: a systematic literature review","volume":"15","author":"Csan\u00e1di","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"2024091012503875500_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.122.001116","article-title":"Identification and characterization of ACP-5862, the major circulating active metabolite of acalabrutinib: both are potent and selective covalent Bruton tyrosine kinase inhibitors","volume":"384","author":"Podoll","year":"2023","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"2024091012503875500_bib7","volume-title":"Calquence [package insert]","year":"2022"},{"issue":"14","key":"2024091012503875500_bib8","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2024091012503875500_bib9","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/10428194.2017.1357177","article-title":"Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment","volume":"59","author":"Papin","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2024091012503875500_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3389\/fonc.2018.00645","article-title":"BCL2-family dysregulation in B-cell malignancies: from gene expression regulation to a targeted therapy biomarker","volume":"8","author":"Tessoulin","year":"2018","journal-title":"Front Oncol"},{"key":"2024091012503875500_bib11","volume-title":"Venclexta [package insert]","year":"2022"},{"issue":"5","key":"2024091012503875500_bib12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.13149","article-title":"Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways","volume":"168","author":"Zhao","year":"2015","journal-title":"Br J Haematol"},{"issue":"13","key":"2024091012503875500_bib13","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.3390\/cancers14133229","article-title":"Tumor microenvironment and immunotherapy-based approaches in mantle cell lymphoma","volume":"14","author":"Saleh","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"13","key":"2024091012503875500_bib14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024091012503875500_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13045-021-01188-x","article-title":"Concurrent ibrutinib plus venetoclax in relapsed\/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study","volume":"14","author":"Wang","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"suppl 2","key":"2024091012503875500_bib16","article-title":"Ibrutinib combined with venetoclax in patients with relapsed\/refractory mantle cell lymphoma: primary analysis results from the randomized phase 3 Sympatico study [abstract LBA-2]","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024091012503875500_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2022-163018","article-title":"Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network [abstract]","volume":"140","author":"Dreyling","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2024091012503875500_bib18","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","article-title":"Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma","volume":"128","author":"Chiron","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2024091012503875500_bib19","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"suppl 16","key":"2024091012503875500_bib20","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1200\/JCO.2023.41.16_suppl.7546","article-title":"Safety and efficacy of ABR in pts with TN or R\/R MCL: Ph Ib trial [abstract 7546]","volume":"41","author":"Phillips","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2024091012503875500_bib21","author":"Wang","year":"2021"},{"issue":"27","key":"2024091012503875500_bib22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl_4","key":"2024091012503875500_bib23","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"2024091012503875500_bib24","first-page":"1490","article-title":"Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma","volume":"6","author":"Portell","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2024091012503875500_bib25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(21)00638-0","article-title":"Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (\u226465 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"2024091012503875500_bib26","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.21.02321","article-title":"Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial","volume":"40","author":"Gin\u00e9","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"S2","key":"2024091012503875500_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/hon.3163_99","article-title":"Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphoma\u2014a phase II clinical trial [abstract 099]","volume":"41","author":"Jain","year":"2023","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2024091012503875500_bib28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood-2023-180069","article-title":"A\u00a0multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-na\u00efve, TP53-mutant mantle cell lymphoma [abstract]","volume":"142","author":"Kumar","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2024091012503875500_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41577-021-00522-1","article-title":"The first 12\u00a0months of COVID-19: a timeline of immunological insights","volume":"21","author":"Carvalho","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2024091012503875500_bib30","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/jmv.26404","article-title":"The outcome of COVID-19 in patients with hematological malignancy","volume":"93","author":"Yigenoglu","year":"2021","journal-title":"J\u00a0Med Virol"},{"issue":"5","key":"2024091012503875500_bib31","doi-asserted-by":"crossref","first-page":"e0711","DOI":"10.1097\/HS9.0000000000000711","article-title":"Outcome of COVID-19 in patients with mantle cell lymphoma-report from the European MCL registry","volume":"6","author":"Tilch","year":"2022","journal-title":"Hemasphere"},{"issue":"2","key":"2024091012503875500_bib32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.19087","article-title":"Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL","volume":"204","author":"Shen","year":"2024","journal-title":"Br J Haematol"},{"issue":"16","key":"2024091012503875500_bib33","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2024091012503875500_bib34","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1182\/blood.2021014270","article-title":"Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma","volume":"140","author":"Ferrero","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4539\/2241210\/blooda_adv-2023-012424-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4539\/2241210\/blooda_adv-2023-012424-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T08:51:20Z","timestamp":1725958280000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/17\/4539\/516190\/Acalabrutinib-plus-venetoclax-and-rituximab-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":34,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012424","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}